Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 145 No. 4950 (2015)

Building legitimacy by criticising the pharmaceutical industry: a qualitative study among prescribers and local opinion leaders

  • Anne-Laure Pittet
  • Michael Saraga
  • Friedrich Stiefel
DOI
https://doi.org/10.4414/smw.2015.14240
Cite this as:
Swiss Med Wkly. 2015;145:w14240
Published
29.11.2015

Summary

PRINCIPLES: The literature has described opinion leaders not only as marketing tools of the pharmaceutical industry, but also as educators promoting good clinical practice. This qualitative study addresses the distinction between the opinion-leader-as-marketing-tool and the opinion-leader-as-educator, as it is revealed in the discourses of physicians and experts, focusing on the prescription of antidepressants. We explore the relational dynamic between physicians, opinion leaders and the pharmaceutical industry in an area of French-speaking Switzerland.

METHODS: Qualitative content analysis of 24 semistructured interviews with physicians and local experts in psychopharmacology, complemented by direct observation of educational events led by the experts, which were all sponsored by various pharmaceutical companies.

RESULTS: Both physicians and experts were critical of the pharmaceutical industry and its use of opinion leaders. Local experts, in contrast, were perceived by the physicians as critical of the industry and, therefore, as a legitimate source of information. Local experts did not consider themselves opinion leaders and argued that they remained intellectually independent from the industry. Field observations confirmed that local experts criticised the industry at continuing medical education events.

CONCLUSIONS: Local experts were vocal critics of the industry, which nevertheless sponsor their continuing education. This critical attitude enhanced their credibility in the eyes of the prescribing physicians. We discuss how the experts, despite their critical attitude, might still be beneficial to the industry’s interests.

References

  1. Collier J, Iheanacho I. The pharmaceutical industry as an informant. Lancet. 2002;360(9343):1405–9.
  2. Hafemeister TL, Bryan SP. Beware Those Bearing Gifts: Physicians’ Fiduciary Duty to Avoid Pharmaceutical Marketing. U Kan L Rev. 2008;57(3):491–537.
  3. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement. BMJ. 2003;326(7400):1189–92.
  4. Lexchin J. Interactions between physicians and the pharmaceutical industry: what does the literature say? CMAJ. 1993;149(10):1401–7.
  5. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283(3):373–80.
  6. Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med. 2007;4(9):1429–33.
  7. Smith R. Curbing the influence of the drug industry: a British view. PLoS Med. 2005;2(9):821–3.
  8. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002;324(7342):886–91.
  9. Moynihan R. Doctors and drug companies: Is the dangerous liaison drawing to an end? Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 2009;103(3):141–8.
  10. Sismondo S. Key Opinion Leaders and the Corruption of Medical Knowledge: What the Sunshine Act Will and Won’t Cast Light On. J Law Med Ethics. 2013;41(3):635–43.
  11. Moynihan R. Key opinion leaders: independent experts or drug representatives in disguise? BMJ. 2008;336(7658):1402–3.
  12. Breen KJ. The medical profession and the pharmaceutical industry: when will we open our eyes? Med J Aust. 2004;180(8):409–10.
  13. Sah S, Fugh‐Berman A. Physicians under the influence: social psychology and industry marketing strategies. J Law Med Ethics. 2013;41(3):665–72.
  14. Meffert JJ. Key opinion leaders: where they come from and how that affects the drugs you prescribe. Dermatol Ther. 2009;22(3):262–8.
  15. Sismondo S. ‘You’re Not Just a Paid Monkey Reading Slides: ’How Key Opinion Leaders Explain and Justify Their Work. Edmond J Safra Working Papers. 2013(26):1–29.
  16. Prescrire. Key opinion leaders: used as a marketing tool by drug companies. Prescrire Int. 2012;21(128):163–5.
  17. Hensley S, Martinez B. To sell their drugs, companies increasingly rely on doctors. Wall Street Journal (Eastern ed.). 2005;A1, A2.
  18. Thomson O’Brien M, Oxman A, Haynes R, Davis D, Freemantle N, Harvey E. Local opinion leaders: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2000;(2):CD000125.
  19. Flodgren G, Parmelli E, Doumit G, Gattellari M, O’Brien MA, Grimshaw J, et al. Local opinion leaders: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2011;(8):CD000125.
  20. Curran GM, Thrush CR, Smith JL, Owen RR, Ritchie M, Chadwick D. Implementing research findings into practice using clinical opinion leaders: barriers and lessons learned. Jt Comm J Qual Patient Saf. 2005;31(12):700–7.
  21. Carpenter CR, Sherbino J. How does an “opinion leader” influence my practice? CJEM. 2010;12(5):431–4.
  22. Locock L, Dopson S, Chambers D, Gabbay J. Understanding the role of opinion leaders in improving clinical effectiveness. Soc Sci Med. 2001;53(6):745–57.
  23. Borbas C, Morris N, McLaughlin B, Asinger R, Gobel F. The role of clinical opinion leaders in guideline implementation and quality improvement. Chest. 2000;118(2 Suppl):24S–32S.
  24. Ryan DP, Marlow B, Fisher R. Educationally influential physicians: the need for construct validation. J Contin Educ Health Prof. 2002;22(3):160–9.
  25. Pittet A.-L. L’orientation de la prescription médicale par l’industrie pharmaceutique. Influence des visiteurs médicaux et des leaders d’opinion sur la prescription de médecins généralistes et psychiatres en Suisse francophone. PhD thesis. Université de Lausanne; to be published.
  26. Green J, Thorogood N. Qualitative methods for health research. Sage; 2014.
  27. Morgan DL. Qualitative content analysis: A guide to paths not taken. Qual Health Res. 1993;3(1):112–21.
  28. Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000;23(4):334–40.
  29. Fugh-Berman A. Key Opinion Leaders: Thus are our medical meetings managed. BMJ. 2008;337(7662):128–9.
  30. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
  31. Goldacre B. Bad Pharma: How drug companies mislead doctors and harm patients. Fourth Estate; 2012.
  32. Wilde O. The Picture of Dorian Gray. 1891. Harmonsworth: Penguin Books; 1985.

Most read articles by the same author(s)